

Development of a method for quantitative metabolite profiling of pharmaceutical drugs using HPLC-ICP-MS following pre-column derivatization of their amino and hydroxyl groups using 4-aminopyridine as a model compound

Sanwang Li ^a, Filip Cuyckens ^b, Frederic Lynen ^c, Frank Vanhaecke ^a

^a Ghent University, Department of Chemistry, Atomic and Mass Spectrometry (A&MS) research unit, Campus Sterre, Krijgslaan 281-S12, 9000 Ghent, Belgium

^b Janssen R&D, Drug Metabolism & Pharmacokinetics, Turnhoutseweg 30, 2340 Beerse, Belgium

^c Ghent University, Department of Organic and Macromolecular Chemistry, Separation Science group, Campus Sterre, Krijgslaan 281-S4-bis, 9000 Ghent, Belgium

Table of contents

<i>Figure S-1: Investigation of the effect of the reaction temperature</i>	S-2
<i>Figure S-2: Investigation of the effect of the reaction time</i>	S-3
<i>Figure S-3: Investigation of the effect of the TEA concentration</i>	S-4
<i>Figure S-4: Investigation of the effect of the reagent concentration</i>	S-5
<i>Figure S-5: Investigation of the effect of the spray chamber</i>	S-6

Figure S-1 Investigation of the effect of the reaction temperature: HPLC-UV chromatograms of 4-aminopyridine and 3-hydroxy-4-aminopyridine standard, derivatized blank plasma and derivatized spiked plasma at room temperature, 40 °C, 50 °C and 60 °C for monitoring the starting compounds (A) and their derivatives (B) in the derivatized plasma sample.

Peaks: 1: 4-aminopyridine; 2: 3-hydroxy-4-aminopyridine; 3: derivative of 4-aminopyridine; 4: derivative of 3-hydroxy-4-aminopyridine




Figure S-2 Investigation of the effect of the reaction time: HPLC-UV chromatograms of 4-aminopyridine and 3-hydroxy-4-aminopyridine standard, derivatized blank plasma and derivatized spiked plasma at room temperature for 15 min, 30 min and 60 min reaction time for monitoring the starting compounds (A) and their derivatives (B) in the derivatized plasma sample.

Peaks: 1: 4-aminopyridine; 2: 3-hydroxy-4-aminopyridine; 3: derivative of 4-aminopyridine; 4: derivative of 3-hydroxy-4-aminopyridine




Figure S-3 Investigation of the effect of the TEA concentration: HPLC-UV chromatograms of 4-aminopyridine and 3-hydroxy-4-aminopyridine standard, derivatized blank plasma and derivatized spiked plasma with 0.4 mM, 1 mM, 2 mM and 4 mM of TEA solution for monitoring the starting compounds (A) and their derivatives (B) in the derivatized plasma sample.

Peaks: 1: 4-aminopyridine; 2: 3-hydroxy-4-aminopyridine; 3: derivative of 4-aminopyridine; 4: derivative of 3-hydroxy-4-aminopyridine




Figure S-4 Investigation of the effect of the reagent concentration: HPLC-UV chromatograms of 4-aminopyridine and 3-hydroxy-4-aminopyridine standard, derivatized blank plasma (A) and derivatized spiked plasma (B) with 0.4 mM, 1 mM, 2 mM and 4 mM of 4-IC solution for monitoring the starting compounds (A) and their derivatives (B) in the derivatized plasma sample.

Peaks: 1: 4-aminopyridine; 2: 3-hydroxy-4-aminopyridine; 3: derivative of 4-aminopyridine; 4: derivative of 3-hydroxy-4-aminopyridine




Figure S-5 Investigation of the effect of the spray chamber: iodine chromatograms of a derivatized spiked plasma sample with a Scott-type spray chamber (blue) and with a cyclonic spray chamber.

Peaks: 1: derivative of 4-aminopyridine; 2: derivative of 3-hydroxy-4-aminopyridine

